These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 3175328)

  • 1. Beneficial mechanisms of action of a prostacyclin enhancing agent in splanchnic artery occlusion shock.
    Aoki N; Siegfried M; Tsao P; Lento P; Lefer AM
    Res Commun Chem Pathol Pharmacol; 1988 Jun; 60(3):275-89. PubMed ID: 3175328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protective effects of thromboxane receptor blockade in splanchnic artery occlusion shock.
    Aoki N; Lefer AM
    Methods Find Exp Clin Pharmacol; 1988 Jul; 10(7):413-8. PubMed ID: 3419244
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of prostacyclin and taprostene in splanchnic artery occlusion shock.
    VanAntwerp DR; Hedley LR; Spires DA; Strosberg AM; Johnson G; Lefer AM
    Eicosanoids; 1991; 4(1):15-20. PubMed ID: 2059456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel beneficial mechanisms of defibrotide, a prostacyclin enhancing agent in splanchnic artery occlusion and reperfusion in rats.
    Ma XL; Porta R; Pescador R; Lefer AM
    Methods Find Exp Clin Pharmacol; 1991 Dec; 13(10):667-74. PubMed ID: 1663194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of adenosine, an adenosine-A1 antagonist, and their combination in splanchnic occlusion shock in rats.
    Karasawa A; Rochester JA; Lefer AM
    Circ Shock; 1992 Feb; 36(2):154-61. PubMed ID: 1582007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-shock effects of human superoxide dismutase in splanchnic artery occlusion (SAO) shock.
    Bitterman H; Aoki N; Lefer AM
    Proc Soc Exp Biol Med; 1988 Jul; 188(3):265-71. PubMed ID: 3393543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protective effects of a novel 21-aminosteroid during splanchnic artery occlusion shock.
    Johnson G; Lefer AM
    Circ Shock; 1990 Feb; 30(2):155-64. PubMed ID: 2311204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of a novel peptide leukotriene receptor antagonist, Ly-163443, in splanchnic artery occlusion shock.
    Bitterman H; Lefer AM
    Prostaglandins Leukot Essent Fatty Acids; 1988 May; 32(2):63-70. PubMed ID: 3406041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute effects of unsaturated fatty acids in splanchnic artery occlusion shock.
    Aoki N; Siegfried M; Tsao P; Lefer AM
    Prostaglandins Leukot Essent Fatty Acids; 1989 Aug; 37(2):89-95. PubMed ID: 2550971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protective effects of the specific thromboxane receptor antagonist (+)-S145Na in splanchnic artery occlusion shock in rats.
    Furlan LE; Johnson G; Siegfried M; Lefer AM
    J Pharmacol Exp Ther; 1990 May; 253(2):525-9. PubMed ID: 2140129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protection of endothelial damage and systemic shock by benidipine, a calcium antagonist, in rats subjected to splanchnic ischemia and reperfusion.
    Karasawa A; Rochester JA; Ma XL; Lefer AM
    Circ Shock; 1991 Mar; 33(3):135-41. PubMed ID: 2044207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beneficial effects of two forms of NO administration in feline splanchnic artery occlusion shock.
    Aoki N; Johnson G; Lefer AM
    Am J Physiol; 1990 Feb; 258(2 Pt 1):G275-81. PubMed ID: 2305894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel mechanism of action of a prostacyclin enhancing agent in haemorrhagic shock.
    Bitterman H; Lefer DJ; Lefer AM
    Naunyn Schmiedebergs Arch Pharmacol; 1988 Jun; 337(6):679-86. PubMed ID: 3063971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of hyperbaric oxygen in circulatory shock induced by splanchnic artery occlusion and reperfusion in rats.
    Bitterman H; Bitterman N; Melamed Y; Cohen L
    Can J Physiol Pharmacol; 1989 Sep; 67(9):1033-7. PubMed ID: 2598128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protective actions of a leukotriene B4 antagonist in splanchnic ischemia and reperfusion in rats.
    Karasawa A; Guo JP; Ma XL; Tsao PS; Lefer AM
    Am J Physiol; 1991 Aug; 261(2 Pt 1):G191-8. PubMed ID: 1651656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beneficial effects of a specific leukotriene receptor antagonist in splanchnic artery occlusion shock.
    Lento PH; Saukkonen K; Aoki N; Lefer AM; Slivjak MJ; Smith EF
    Eur J Pharmacol; 1989 Jun; 165(2-3):241-9. PubMed ID: 2550251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platelet activating factor interaction with tumor necrosis factor and myocardial depressant factor in splanchnic artery occlusion shock.
    Zingarelli B; Squadrito F; Ioculano M; Altavilla D; Bussolino F; Campo GM; Caputi AP
    Eur J Pharmacol; 1992 Nov; 222(1):13-9. PubMed ID: 1468489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beneficial effects of transforming growth factor-beta and tissue plasminogen activator in splanchnic artery occlusion and reperfusion in cats.
    Karasawa A; Guo JP; Ma XL; Lefer AM
    J Cardiovasc Pharmacol; 1991 Jul; 18(1):95-105. PubMed ID: 1719297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amelioration of splanchnic artery occlusion (SAO) shock by cysteine.
    Galvin MJ; Lefer AM
    Adv Shock Res; 1978; 1():261-70. PubMed ID: 262085
    [No Abstract]   [Full Text] [Related]  

  • 20. Mechanisms of inhibition of nitric oxide production in a murine model of splanchnic artery occlusion shock.
    Ma XL; Johnson G; Lefer AM
    Arch Int Pharmacodyn Ther; 1991; 311():89-103. PubMed ID: 1789714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.